Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Ribo Life Science realises series C2 round
SAIC Motor fund Hengxu Investment and a Sinopharm-backed joint venture were among the investors in a $66.3m round for the RNA drug developer.
Zentalis zips to $165m IPO
The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.
Legend Biotech lands $151m
Lilly Asia Ventures and Johnson & Johnson Innovation – JJDC are both investing in a series A round for the cell therapy developer, a spinoff from Genscript Biotech.
VenBio visits corporates for $394m third fund
Undisclosed pharmaceutical companies were among the investors in the venture firm's third fund, which will target biopharmaceutical developers.
Corporate venturing deal net: 30 March-3 April 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
AM-Pharma amplifies latest round to $182m
Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.
6 Dimensions supports $125m round for iTeos
The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.
Pandion packs in $80m
Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.

Other News

Aspen Neuroscience ascends with $70m
The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.
Affinia affirms $60m series A
Lonza participated in the gene therapy developer's series A round alongside Partners Innovation Fund, having also licensed technology to the startup.
Olive collects $51m
General Catalyst led a $51m round for the Ascension-backed healthcare automation technology developer, which has now received $119m in total.
Doctor Anywhere locates $27m
IHH Healthcare participated in a series B round that boosted the care provider's capital base to more than $40m.
Hualan Biological Vaccines hooks $292m
Hillhouse Capital and Chen Yi Investment are making a secondary investment in the Hualan Biological Engineering spinoff which is now valued at more than $1.9bn.
Avail puts $15m in its eyeline
Avail Medsystems, a remote medical device startup which counts Baidu Ventures as an investor, has captured $15m in new funding.

Editor's Picks

Vertex veers to Semma for $950m acquisition
Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.
Carroll retires from Lilly after two decades
After 22 years at Eli Lilly that included laying the groundwork for its corporate venturing activities, senior vice-president of corporate business development Darren Carroll is retiring.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
test reg